1. Home
  2. ORIS vs HCWB Comparison

ORIS vs HCWB Comparison

Compare ORIS & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORIS
  • HCWB
  • Stock Information
  • Founded
  • ORIS 2014
  • HCWB 2018
  • Country
  • ORIS China
  • HCWB United States
  • Employees
  • ORIS N/A
  • HCWB N/A
  • Industry
  • ORIS Farming/Seeds/Milling
  • HCWB Biotechnology: Pharmaceutical Preparations
  • Sector
  • ORIS Consumer Staples
  • HCWB Health Care
  • Exchange
  • ORIS Nasdaq
  • HCWB Nasdaq
  • Market Cap
  • ORIS 19.5M
  • HCWB 16.1M
  • IPO Year
  • ORIS 2024
  • HCWB 2021
  • Fundamental
  • Price
  • ORIS $0.87
  • HCWB $6.04
  • Analyst Decision
  • ORIS
  • HCWB Strong Buy
  • Analyst Count
  • ORIS 0
  • HCWB 1
  • Target Price
  • ORIS N/A
  • HCWB $35.00
  • AVG Volume (30 Days)
  • ORIS 974.4K
  • HCWB 2.0M
  • Earning Date
  • ORIS 02-21-2025
  • HCWB 05-15-2025
  • Dividend Yield
  • ORIS N/A
  • HCWB N/A
  • EPS Growth
  • ORIS N/A
  • HCWB N/A
  • EPS
  • ORIS 0.17
  • HCWB N/A
  • Revenue
  • ORIS $15,014,000.00
  • HCWB $1,445,145.00
  • Revenue This Year
  • ORIS N/A
  • HCWB N/A
  • Revenue Next Year
  • ORIS N/A
  • HCWB N/A
  • P/E Ratio
  • ORIS $5.12
  • HCWB N/A
  • Revenue Growth
  • ORIS N/A
  • HCWB N/A
  • 52 Week Low
  • ORIS $0.82
  • HCWB $5.00
  • 52 Week High
  • ORIS $56.01
  • HCWB $100.80
  • Technical
  • Relative Strength Index (RSI)
  • ORIS N/A
  • HCWB 36.83
  • Support Level
  • ORIS N/A
  • HCWB $7.55
  • Resistance Level
  • ORIS N/A
  • HCWB $6.68
  • Average True Range (ATR)
  • ORIS 0.00
  • HCWB 0.64
  • MACD
  • ORIS 0.00
  • HCWB -0.20
  • Stochastic Oscillator
  • ORIS 0.00
  • HCWB 9.37

About ORIS Oriental Rise Holdings Limited Ordinary Shares

Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Share on Social Networks: